New Psoriasis Pill Works as Well as Injections in Trials

People with severe plaque psoriasis have faced a frustrating choice for years: take a pill that barely works or endure the hassle of regular injections for clear skin. That dilemma might finally be over.

Clinical trials involving nearly 1,800 adults across 21 countries show a new once-daily pill called zasocitinib delivers results as powerful as injectable treatments. About 70% of participants achieved clear or almost clear skin within just 16 weeks.

The numbers tell an even more compelling story when compared to existing oral medications. Only 30% of patients taking apremilast, a widely used psoriasis pill, saw significant improvement. Zasocitinib more than doubled that success rate.

Plaque psoriasis causes skin cells to multiply too quickly, creating thick, scaly red patches covered in silvery scales. During flare-ups, the condition triggers intense itching and burning sensations that disrupt daily life.

Dr. Melinda Gooderham, a dermatologist in Ontario who led the research, emphasized the significance of these findings. "Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies," she explained at the American Academy of Dermatology meeting in Denver last month.

The medication worked surprisingly fast. Many patients noticed their skin starting to clear within just four weeks of starting treatment.

The Bright Side

The results proved lasting, which matters immensely for people managing a chronic condition. Of patients who achieved clear skin at nine months, over 90% maintained those results after more than a year of daily use.

Safety results brought more good news. No unexpected concerns emerged during the trials, and the most common side effects were mild, like upper respiratory infections similar to the common cold. About 6.5% of patients experienced acne, a known side effect of TYK2 inhibitor medications like zasocitinib.

Takeda Pharmaceuticals plans to submit the drug to the FDA for approval within the next year. If approved, zasocitinib would offer millions of Americans with moderate to severe plaque psoriasis a genuine alternative to injections without sacrificing results.

For people who've spent years navigating the trade-offs of psoriasis treatment, the promise of clear skin in a daily pill represents more than medical progress—it's freedom.